Literature DB >> 17024424

Liver glycogen bodies: ground-glass hepatocytes in transplanted patients.

Pablo A Bejarano1, Monica T Garcia, Maria M Rodriguez, Phillip Ruiz, Andreas G Tzakis.   

Abstract

Ground-glass hepatocytes have been described in Lafora's disease, fibrinogen deposition, hepatitis B, type IV glycogenosis, and alcohol aversion (cyanamide) therapy. We encountered ground-glass hepatocytes with intracytoplasmic inclusions in four liver biopsies from three transplanted patients who had none of the above-mentioned underlying diseases. One patient was a 4-year-old boy who had a kidney transplant for severe ureterovesical reflux. Patient 2 was a 52-year-old man who had two liver transplants because of hepatitis C. The third patient was a 7-month-old girl who underwent a multivisceral transplant because of necrotizing enterocolitis and liver failure induced by total parenteral nutrition. The patients developed liver abnormalities from 45 days to 4 years after their transplants. The livers showed conspicuous ground-glass hepatocytes in 90% of the children's samples and 30% of the adult liver cells. The cytoplasmic bodies stained strongly for Gomori methenamine-silver; they were positive for periodic acid-Schiff without diastase, but negative after diastase digestion. They were negative for colloidal iron and hepatitis B core and surface antigens. Electron microscopy revealed non-membrane bound aggregates of glycogen. Idiopathic ground-glass hepatocytes occur in transplanted patients and represent accumulation of altered glycogen. However, their clinical significance and cause are not entirely elucidated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024424     DOI: 10.1007/s00428-006-0286-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes of carriers.

Authors:  S Hadziyannis; M A Gerber; C Vissoulis; H Popper
Journal:  Arch Pathol       Date:  1973-11

2.  Rifampicin hepatitis. A clinical and histological study.

Authors:  P J Scheuer; J A Summerfield; S Lal; S Sherlock
Journal:  Lancet       Date:  1974-03-16       Impact factor: 79.321

3.  Genetic and immunological characterization of fibrinogen inclusion bodies in patients with hepatic fibrinogen storage and liver disease.

Authors:  D Medicina; G Fabbretti; S O Brennan; P M George; B Kudryk; F Callea
Journal:  Ann N Y Acad Sci       Date:  2001       Impact factor: 5.691

4.  Ground-glass hepatocytes in unselected liver biopsies. ultrastructure and relationship to hepatitis B surface antigen.

Authors:  K Winckler; U Junge; W Creutzfeldt
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

5.  Use of a monoclonal antibody against Lafora bodies for the immunocytochemical study of ground-glass inclusions in hepatocytes due to cyanamide.

Authors:  K Hashimoto; Y Hoshii; M Takahashi; S Mitsuno; N Hanai; Y Watanabe; T Ishihara
Journal:  Histopathology       Date:  2001-07       Impact factor: 5.087

6.  Ground-glass hepatocytes with Lafora body like inclusions--histochemical, immunohistochemical and electronmicroscopic characterization.

Authors:  I O Ng; R P Sturgess; R Williams; B Portmann
Journal:  Histopathology       Date:  1990-08       Impact factor: 5.087

7.  Co-existence of hepatocyte ground-glass inclusions from several causes.

Authors:  C Alonso-Marti; A Moreno; A Barat; J C Solera; H Oliva
Journal:  Histopathology       Date:  1990-03       Impact factor: 5.087

8.  Predictive factors for development of diabetes mellitus post-heart transplant.

Authors:  L Martínez-Dolz; L Almenar; L Martínez-Ortiz; M A Arnau; C Chamorro; J Moro; A Osa; J Rueda; C García; M Palencia
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

Review 9.  New-onset diabetes after liver transplantation: from pathogenesis to management.

Authors:  Piero Marchetti
Journal:  Liver Transpl       Date:  2005-06       Impact factor: 5.799

10.  Pale bodies in hepatocellular carcinoma.

Authors:  W S Moon; H C Yu; M J Chung; M J Kang; D G Lee
Journal:  J Korean Med Sci       Date:  2000-10       Impact factor: 2.153

View more
  3 in total

1.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

2.  Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype.

Authors:  Peter Bannasch
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

3.  Pathomorphogenesis of Glycogen-Ground Glass Hepatocytic Inclusions (Polyglucosan Bodies) in Children after Liver Transplantation.

Authors:  Francesco Callea; Paola Francalanci; Chiara Grimaldi; Francesca Diomedi Camassei; Rita Devito; Fabio Facchetti; Rita Alaggio; Emanuele Bellacchio
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.